- Home
- HSTM vs RCUS Comparison
HSTM vs RCUS Comparison
Compare HSTM & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- RCUS
- Stock Information
- Founded
- HSTM 1990
- RCUS 2015
- Country
- HSTM United States
- RCUS United States
- Employees
- HSTM N/A
- RCUS N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- RCUS Health Care
- Exchange
- HSTM Nasdaq
- RCUS Nasdaq
- Market Cap
- HSTM 851.7M
- RCUS 906.4M
- IPO Year
- HSTM 2000
- RCUS 2018
- Fundamental
- Price
- HSTM $28.10
- RCUS $9.24
- Analyst Decision
- HSTM Hold
- RCUS Buy
- Analyst Count
- HSTM 2
- RCUS 11
- Target Price
- HSTM $29.00
- RCUS $25.33
- AVG Volume (30 Days)
- HSTM 277.4K
- RCUS 1.2M
- Earning Date
- HSTM 05-05-2025
- RCUS 05-06-2025
- Dividend Yield
- HSTM 0.44%
- RCUS N/A
- EPS Growth
- HSTM 8.37
- RCUS N/A
- EPS
- HSTM 0.63
- RCUS N/A
- Revenue
- HSTM $292,371,000.00
- RCUS $141,000,000.00
- Revenue This Year
- HSTM $4.98
- RCUS N/A
- Revenue Next Year
- HSTM $5.13
- RCUS $29.83
- P/E Ratio
- HSTM $44.61
- RCUS N/A
- Revenue Growth
- HSTM 3.36
- RCUS N/A
- 52 Week Low
- HSTM $25.84
- RCUS $6.50
- 52 Week High
- HSTM $34.24
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- HSTM 41.19
- RCUS 57.16
- Support Level
- HSTM $27.74
- RCUS $8.55
- Resistance Level
- HSTM $28.36
- RCUS $9.61
- Average True Range (ATR)
- HSTM 0.67
- RCUS 0.50
- MACD
- HSTM 0.12
- RCUS 0.06
- Stochastic Oscillator
- HSTM 51.02
- RCUS 72.59
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.